Boston Scientific (BSX) Getting Positive Media Coverage, Report Shows
News articles about Boston Scientific (NYSE:BSX) have been trending positive on Monday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific earned a news impact score of 0.43 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 45.9160128966052 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System (finance.yahoo.com)
- Remarkable Stock News Analysis: Boston Scientific Corporation (NYSE:BSX) – Market Breaking Point (press release) (journalfinance.net)
- Boston Scientific Corporation (NYSE:BSX) – An Eye on Price to Earnings Ratio – Nasdaq Journal (press release) (nasdaqjournal.com)
- Financial Comparison: Boston Scientific (BSX) versus Viveve Medical (VIVE) (americanbankingnews.com)
- 6 Reasons Why Needham Upgraded Boston Scientific (finance.yahoo.com)
A number of research analysts recently weighed in on the company. TheStreet downgraded Boston Scientific from a “b” rating to a “c+” rating in a research note on Thursday. Needham & Company LLC raised Boston Scientific from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $25.04 to $32.00 in a research note on Friday. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the stock a “buy” rating in a research note on Monday, December 4th. Cowen set a $31.00 price target on Boston Scientific and gave the stock a “buy” rating in a research note on Thursday, November 30th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $31.00 price target on shares of Boston Scientific in a research note on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific has an average rating of “Buy” and a consensus target price of $30.97.
Boston Scientific (NYSE:BSX) traded down $0.27 during mid-day trading on Monday, hitting $25.50. The stock had a trading volume of 8,860,020 shares, compared to its average volume of 7,018,641. The company has a market capitalization of $35,100.00, a price-to-earnings ratio of 21.12, a PEG ratio of 1.99 and a beta of 0.95. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. Boston Scientific has a 52 week low of $20.81 and a 52 week high of $29.93.
Boston Scientific (NYSE:BSX) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.27 earnings per share. equities research analysts anticipate that Boston Scientific will post 1.25 earnings per share for the current year.
In other news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The shares were acquired at an average price of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $26.04, for a total value of $260,400.00. Following the completion of the transaction, the executive vice president now owns 154,681 shares in the company, valued at approximately $4,027,893.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 424,698 shares of company stock worth $12,273,553. 0.74% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Boston Scientific (BSX) Getting Positive Media Coverage, Report Shows” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/11/boston-scientific-bsx-getting-positive-media-coverage-report-shows.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.